ClinicalTrials.gg
RecruitingNCT03594318Updated Jul 20, 2018

Versailles Hospital Cardiac Arrest Registry

An observational study in Cardiac Arrest, sponsored by Versailles Hospital. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-07-20.

Sponsored by Versailles Hospital · Observational

How we know

From the registry’s dates

  • Started Jan 2006; still recruiting 20 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 106 studies in Heart Arrest with a site in France — 32 open to participants now, 33 under way, 3 of them phase 3. Heart Arrest · France.

Planned enrollment
5th of 47
1,000 · median 150
Started
2006
with 2 others
Observational
47 of 106
17 open now
Primary completion
2026-12
later than 11 of 32 live
Registered
51st of 106
by date

Among the 106 studies in Heart Arrest with a site in France, this one is the 5th largest by planned enrollment of the 47 observational ones that give a count, is one of 3 that started in 2006, is one of 47 observational ones, reaches primary completion later than 11 of the 32 other live ones, and was the 51st registered.

Heart Arrest

927 studies on the registry are indexed under Heart Arrest; 227 are open to participants now.

Browse Heart Arrest studies →

Open to participants now

32 of the 106 studies in Heart Arrest with a site in France are open now. Recruiting first, the newest first:

27 more — sign in →

All 32 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 157 Heart Arrest studies recruiting now, 109 (69%) set no upper age limit and 28 (18%) stop at 75 or younger; 30 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 106 studies in Heart Arrest with a site in France, or all of them as a file.
02

Study summary

Out-of-hospital and in-hospital cardiac arrest (CA) requiring intensive care unit management.

Data collection using a standardized form : demographic data and data related to the CA according to the Utstein guidelines.. Circumstances of onset, dates and times of onset and control of abnormal movements (myoclonus and.or seizures).

On-scene clinical findings, pre-hospital and hospital care providers, timing of various treatments and supportive care, results of etiological investigations, cause of CA. Dates and times of EEG monitoring, EEG results. Outcomes including vital status and Cerebral Performance Category scale score at ICU and hospital discharge, day-90 and 1-year after CA and determined based on data in the ICU and/or hospital/neurologist charts and/or general practitionner phone interview.

03

Conditions studied

  • Cardiac Arrest

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Cardiac arrest requiring Intensive Care Unit Management

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Cardiac arrest requiring Intensive Care Unit management
  • Age >= 18 years

Exclusion criteria

Exclusion Criteria:

  • Refusal to participate
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Target follow-up
24 Years
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Long term favorable outcome

    A favorable outcome is defined by a Cerebral Performance Category scale score (CPC) of 1 or 2. The Cerebral Performance Category scale score will be determined according to hospital charts and/or general practitioner phone interview. The CPC score : \[5: Death, 4: Persistent vegetative state, 3: Severe disability, 2: Moderate disability, 1 : Low disability\]

    Time frame: 1 year

Secondary outcomes

  1. Short term favorable outcome

    A favorable outcome is defined by a Cerebral Performance Category scale score (CPC) of 1 or 2. The Cerebral Performance Category scale score will be determined according to hospital charts and/or general practitioner phone interview. The CPC score : \[5: Death, 4: Persistent vegetative state, 3: Severe disability, 2: Moderate disability, 1 : Low disability\]

    Time frame: 3 months

  2. Postanoxic Status Epilepticus

    Postanoxic Status Epilepticus occurence as defined by EEG abnormalities based on the Salzburg Criteria

    Time frame: 28 days

  3. Complications of anticoagulant/ antiplatelet therapies

    Any bleeding requiring \>2 Units Red Blood Cell transfusion

    Time frame: 28 days

  4. Short term quality of life as assessed by the Short Form (36) Health Survey (SF36)

    Description of global SF36 score and each of its eight sections (vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, mental health).

    Time frame: 3 months

  5. Long term quality of life as assessed by the Short Form (36) Health Survey (SF36)

    Description of global SF36 score and each of its eight sections (vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, mental health).

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2006 (actual). Primary completion is estimated for Dec 2026, 251 months after the start.

Of 169 non-industry observational studies under Heart Arrest, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 96. This study's planned 251 months is above that.

Counting every sponsor, half of 176 studies reached it within 41 months; a quarter within 18 and three quarters within 90.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2018
First posted
Jul 20, 2018
StartActual
Jan 2006
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2030
Last update
Jul 20, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03594318
Lead sponsor
Versailles Hospital
Responsible party
LEGRIEL stephane (study principal investigator, Versailles Hospital) — Principal investigator
First posted
Jul 20, 2018
Start date
Jan 2006
Primary completion
Dec 2026 (estimated)
Completion
Dec 2030 (estimated)
Last update
Jul 20, 2018

Study contacts

Legriel Stephane, MD
Contact
slegriel@ch-versailles.fr
Legriel Stephane, MD
study director · Intensive care unit

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion